Last reviewed · How we verify
PF-07321332 Dose 1 (pf-07321332-dose-1)
PF-07321332, developed by Pfizer Inc., is an investigational antiviral drug designed to inhibit the main protease of SARS-CoV-2, the virus that causes COVID-19. It is being evaluated in combination with ritonavir as a potential treatment for mild to moderate COVID-19 in non-hospitalized patients. The drug has shown promise in reducing viral load and the risk of hospitalization or death in clinical trials. However, it does not have an FDA label yet, and its safety profile is still under evaluation.
At a glance
| Generic name | pf-07321332-dose-1 |
|---|---|
| Sponsor | Pfizer |
| Drug class | Protease inhibitor |
| Target | SARS-CoV-2 main protease (Mpro) |
| Phase | FDA-approved |
Approved indications
- COVID-19
Pipeline indications
Common side effects
Drug interactions
- Atazanavir
- Cobicistat
- Darunavir
- Dolutegravir
- Etravirine
- Indinavir
- Lopinavir
- Nelfinavir
- Ritonavir
- Saquinavir
- Tipranavir
- Fosamprenavir
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PF-07321332 Dose 1 CI brief — competitive landscape report
- PF-07321332 Dose 1 updates RSS · CI watch RSS
- Pfizer portfolio CI